Topic oncology

News oncology

• Ablynx receives milestone payment as collaborator receives IND approval for a nanobody in oncology

  Ablynx announced that it has received a €400,000 milestone payment from its collaboration with Novartis. The payment was triggered by the approval of an Investigational New Drug (IND) application from the U.S. Food and Drug Administration for the Phase I clinical trial for a Nanobody® licensed to No more

• Ablynx announces an extension of its global strategic nanobody alliance with Boehringer Ingelheim

  Ablynx announced a two-year extension of the initial five-year research funding by Boehringer Ingelheim of their global strategic alliance to discover, develop and commercialise up to 10 different Nanobody® therapeutics. The extension which will run until September 2014, will allow all the existing more

• 'Cancer Drug Market Will Reach $75 Billion in 2012' visiongain Report Predicts

  A new report by visiongain predicts that the world market for cancer-treating drugs will reach $75 billion for 2012. That revenue forecast appears in Leading Anti-Cancer Drugs and Associated Market 2012-2022, published in February 2012. The new study predicts that overall revenues for anti-cancer tr more

White papers oncology

• Interference and HAMA problems
  

  Immunoassays are bioanalytical methods based on antibodies. These include ELISA, EIA, RIA, Western blotting, protein arrays, lateral flow assays (immuno-chromatography), immunohistochemistry or immuno-PCR. Antibodies detect the substances (analytes) in immunoassays. This detection is always highly specific and only the analytes are detected and bound. This is the theory! Practically any antibody not only binds its analyte. It also binds several other substances, but with very different affinities. more

• Epitope Mapping Using the In Vitro Rapid Translation System RTS 100
  

  The Rapid Translation System (RTS) represents a cell-free system that allows efficient production of protein from linear DNA sequences. This article gives a brief outline of the use of the RTS technology in linear epitope mapping and shows its promise for reducing time-consuming cloning and cell-lysis steps. more

• Analysis of the DNA Methylation Patterns at the BRCA1 CpG Island
  

  Germ-line alterations of the BRCA1 gene confer a lifetime risk of 40% for ovarian cancers and of 40%-80% for ­breast cancers. It is likely that BRCA1 acts as a tumor suppressor gene. BRCA1 involvement in breast cancers does not seem to be restricted to familial cancers. Despite the absence of somatic mutations in the breast tissues, a down regulation of BRCA1 expression is associated with malignancy in human sporadic breast cancers. more

Publications oncology

• Malignancy through cooperation: an evolutionary game theory approach

  Abstract Objective Traditional cancer initiation theory propounds evolution of a monoclonal population of fully transformed tumour cells to form a malignant tumour. Cooperation between surrounding stroma and the tumour also often leads to malignancy. This cooperation may exist as a result of sh more

• Analysis of Clinicopathologic Characteristics and Prognosis of Gastric Cancer in Young and Older Patients

  Background The worldwide incidence of gastric cancer is gradually declining, however it remains the fourth highest in cancer incidence and the second leading cause of cancer death. Gastric cancer in young people is a disturbing problem and the routine screening does not include people less than 35 y more

• Uterine leiomyosarcoma diffusely express disialoganglioside GD2 and bind the therapeutic immunocytokine 14.18-IL2: implications for immunotherapy

  Uterine leiomyosarcoma comprises <1 % of uterine malignancies and is known for its clinically aggressive course. Extrapelvic recurrences are common and often lethal. No adjuvant therapies have been shown to significantly improve overall survival, highlighting the need for new and novel therapies. Ou more

Market studies oncology

• Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - February 2012

  Introduction GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - February 2012” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The repor more

• IDL Biotech AB (IDL B) - Financial and Strategic SWOT Analysis Review

  IDL Biotech AB (IDL Biotech AB) is a Sweden based biotechnology company engaged in developing, manufacturing and marketing of in vitro diagnostics within the areas of oncology and bacteriology. The product pipeline of the company consists of TPS, TPAcyk, MonoTotal and UBC, which are cytokeratin tumo more

• Uzbekistan Pharmaceuticals and Healthcare Report Q2 2012

  BMI View: Uzbekistan’s pharmaceutical market remains one of the fastest growing in the Central and Eastern Europe (CEE) region and its population and currently low levels of per capita pharmaceutical spending gives it the greatest long-term growth potential of any Central Asian market. BMI forecasts more

Websites oncology